10:54 AM EDT, 05/22/2024 (MT Newswires) -- Scholar Rock ( SRRK ) said Wednesday it has started the phase 2 proof-of-concept trial to evaluate the safety and effectiveness of apitegromab in preserving lean muscle mass in persons living with obesity and receiving glucagon-like peptide-1, or GLP-1, receptor agonist.

The trial's results will guide the development of SRK-439, an investigational selective myostatin inhibitor to treat cardiometabolic diseases and obesity, the company said.

Scholar Rock ( SRRK ) also announced new preclinical data suggesting that SRK-439 could preserve lean muscle mass and is suitable for subcutaneous dosing in people with obesity.

Primary data from the apitegromab trial are expected in mid-2025, guiding SRK-439's development and a possible investigational new drug application in 2025, the company said.

Shares of Scholar Rock ( SRRK ) were down 1.7% in recent Wednesday trading.

Price: 12.06, Change: -0.21, Percent Change: -1.71